FDA 483 - Ophtec USA, Inc. - June 24, 2022

An FDA inspection of Ophtec USA, Inc. in Sunrise, FL, a commercial sponsor-monitor, revealed one observation. The firm failed to consistently submit current lists of investigator names and addresses to the FDA at required intervals after investigation approval. This indicates a lapse in regulatory reporting for clinical investigations.